Perimeter Medical Imaging AI Inc
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Adrian Mendes
- Full Time Employees
- 40
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 555 Richmond Street West Toronto ON Canada M5V 3B1
- IPO Date
- Sep 2, 1988
- Website
- perimetermed.com
- Similar Companies
- Business
- Perimeter Medical Imaging AI, Inc. (TSX-V: PINK; OTCQX: PYNKF) develops and commercializes advanced medical imaging tools utilizing optical coherence tomography (OCT) technology to transform cancer surgery by providing real-time, ultra-high-resolution visualization of tissue margins; its FDA-cleared Perimeter S-Series OCT system offers surgeons cross-sectional imaging of excised tissue specimens at the cellular level, including an intraoperative scanning device for up to 10 cm by 10 cm surface areas, specimen-handling consumables to maintain orientation, and an image library with training support; the investigational Perimeter B-Series OCT integrates proprietary ImgAssist AI for automated detection of suspicious tissue during breast-conserving surgeries, supported by machine learning under the ATLAS AI project and a pivotal clinical trial backed by a US$7.4 million grant from the Cancer Prevention and Research Institute of Texas. The company, founded in 2013 and headquartered in Toronto, Canada, with operations in Dallas, Texas, targets surgeons and cancer centers primarily in the United States and Canada, serving breast cancer and other surgical procedures to address unmet needs in margin assessment and re-excision reduction. Recent developments include the September 2025 launch of the OCT-Tissue Surveillance Registry to collect surgical imaging data for AI enhancement and product iteration; a May 2025 Development Support Agreement with Intermountain Health to evaluate clinical, social, and economic benefits of OCT and AI in reducing cancer reoperations; August 2025 appointments of Ted James, MD, as Chief Medical Officer, Abbey Goodman as Vice President of Sales, and Paolo DiPasquale as Vice President of Corporate Development, alongside formation of the Perimeter Industry Advisory Board chaired by Diana Chan; a July 2025 prospectus offering raising gross proceeds of $5.35 million; ongoing FDA substantive review of the Perimeter B-Series Premarket Approval application with a decision anticipated in the first half of 2026 following Breakthrough Device Designation; and commercial expansion with installations at sites like Medical City Dallas Hospital, driving record nine-month 2025 revenue of $1.6 million, up 88% from full-year 2024.
Company News
Perimeter Medical Imaging AI to Participate in the Planet MicroCap Showcase in Toronto
Perimeter Medical Imaging AI Appoints Finance Executive Michelle Caron to Board of Directors
Perimeter Medical Imaging AI, Inc. (PINK:CA) Q2 2026 Earnings Call Transcript
Perimeter Announces Preliminary Second Quarter 2026 Financial Results
Perimeter Schedules Second Quarter 2026 Financial Results Conference Call for August 20th
Intermountain Health Brings Perimeter's Claire™ to the Operating Room, a Landmark in Breast Cancer Surgery Using AI
Perimeter Medical Imaging AI to Participate in the Planet MicroCap Showcase in Las Vegas
Perimeter Selected for INOVAIT Pilot Fund to Advance AI for Breast Cancer Surgery
Perimeter Medical Imaging AI, Inc. (PINK:CA) Q1 2026 Earnings Call Transcript
Perimeter Announces First Quarter 2026 Financial Results
Perimeter Schedules First Quarter 2026 Financial Results Conference Call for May 28th
Perimeter Showcases Claire™ for Intraoperative Breast Cancer Margin Assessment at ASBrS 2026
Perimeter Medical Imaging AI to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
Perimeter Medical Imaging AI, Inc. (PINK:CA) Q4 2025 Earnings Call Transcript
Perimeter Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results Marked by Record Revenues and Improved Operating Performance
Perimeter Schedules Fourth Quarter and Full Year 2025 Financial Results Conference Call for March 31st; Provides Corporate Update
Perimeter Medical Imaging AI's 'Claire' Becomes First FDA-approved AI-Enabled Imaging Device for Breast Cancer Surgery
Perimeter Announces Grant and Cancellation of Stock Options
Perimeter Medical Imaging AI Enters Systemwide Agreement with Intermountain Health
Perimeter Medical Imaging AI, Inc. (PINK:CA) Shareholder/Analyst Call Prepared Remarks Transcript